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10 Isoflavones are important dietary compounds that are con-
sumed with the daily diet and elicit important biological actions.
Here we report on the ability of genistein to partially accumulate
in body depots of male mice, be released following fasting, and
modulate the actions of estradiol and environmental estrogens in
15 reproductive and nonreproductive target organs of estrogen-
reporter mice (ERE-tK-luciferase). After the consumption of 50
mg/kg/day for 3 days, genistein accumulates in body compart-
ments where it remains at functionally active levels for at least 15
days. Following 48 h of fasting, its concentration increased in
20 serum from 99 ± 13 to 163 ± 17nM. These levels are sufficient to
exert an estrogenic effect in the testis and liver, as revealed by
a twofold increase in luciferase gene expression. b-Benzene-
hexachloride (bBHC) given at the concentration of 100 mg/kg/
day for 3 days also accumulates in the body and is released by
25 fasting, reaching serum levels of 176 ± 33nM, upregulating the
luciferase gene in the liver and inhibiting its expression in the
testis. When genistein was given in combination with bBHC at
doses sufficient to induce accumulation of both in body depots, the
genistein mobilized by fasting reversed the action of the mobilized
30 bBHC in the testis. Acute administration of nutritional doses of
genistein inhibited the action of estradiol and reversed the
antiestrogenic action of o,p#-DDT [1,1,1,-trichloro-2(p-chloro-
phenyl)-2-(o-chlorophenyl)ethane] in the liver and the antiestro-
genic action of bBHC in the testis. Genistein had an additive
35 effect with the ER agonist p,p#-DDT [1,1,1,-trichloro-2,2-bis
(p-chlorophenyl)ethane] in the liver. The observed effects may be
relevant to a protective action of phytoestrogens against estrogen
receptor–interacting pollutants as well as the dietary modulation
of estradiol action.
40 Key Words: phytoestrogens; estrogen receptors; estrogen
responsive elements; reporter mice; endocrine disruptors.
There are several chemicals in the environment that are able
to bind to estrogen receptors (ERs) and modulate the tran-
scription of target genes (Kuiper et al., 1998). They include
45man-made by-products of industrial processes that are found as
contaminants in food and water (xenoestrogens) (Lintelmann
et al., 2003) and natural compounds produced by plants
consumed as food or food supplements (phytoestrogens)
(Cornwell et al., 2004).
50People are exposed to nutritional estrogens (mainly iso-
flavones and lignans) (Aldecreutz et al., 1993; Bhakta et al.,
2006) depending on their daily intake of certain vegetables.
Those most exposed are populations eating soy in their daily
diet. Asian populations may eat up to 50 mg/day of the
55isoflavone genistein (Kim and Kwon, 2001; Kimira et al.,
1998; Yamamoto et al., 2001), while for some Western
populations (i.e., the Finnish), the daily intake may not exceed
1 mg/day. Dietary intake of soy produces average blood levels
of isoflavones of over 1lM in Asian populations and in people
60consuming isoflavones supplemented products, and levels 10–
100 times lower in populations with a diet of variable vegetable
content (Adlercreutz et al., 1993; Nettleton et al., 2004; Uehar
et al., 2000; Vedrine et al., 2006). However, blood levels of
40nM or higher have been shown to produce estrogenic effects
65in experiments on animals (Penza et al., 2006). Thus, it is
possible that also concentrations of genistein lower than those
found in Asian diets are estrogenically active in humans.
Nutritional isoflavones can bind ERs (ERa and ERb) and
exert both ER agonist and ER antagonist action in a tissue-
70specific and promoter-specific manner (Schultz et al., 2005).
Genistein is known to exert estrogenic effects at low doses,
through ERa and ERb, although at higher doses it also
productively interacts with other nuclear receptors such as
PPARs (Dang and Lowik, 2004) and affects protein kinases,
75apoptosis, and cell proliferation (Huang et al., 2005; Yu et al.,
2004).
In the human diet, there are also several estrogenic
compounds that do not play a nutritional role, but that are
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present as food contaminants. The most abundant are organo-
80 chlorines such as DDT, b-benzene-hexachloride (bBHC), and
others (Simonich and Hites, 1995); plasticizers (Toda et al.,
2004); phthalates (Inoue et al., 2002); industrial chemicals
such as PCBs and dioxins (Hirai et al., 2004; Safe, 1992);
detergents (Falconer, 2006); flame retardants (Legler and
85 Brouwer, 2003); and heavy metals (Henson and Chedrese,
2004). Several of these substances have chemical structures
that favor their accumulation and persistence in fat tissue from
which they can be mobilized under energetic imbalance (e.g.,
during pregnancy, lactation, disease, and weight loss–inducing
90 diets) and exert estrogenic effects on the whole physiology
(Villa et al., 2004). Phytoestrogens are not considered able to
accumulate in the organism. Following ingestion, their elim-
ination is fast, with 90% being eliminated after 36 h (King and
Bursill, 1998). However, because they are consumed very
95 frequently, a diet containing a normal amount of soy may be
sufficient to maintain a certain estrogenic load in the body.
Using a mouse model in which the pharmacodynamics of an
ER ligand can be studied by the modulation of a convenient
estrogen-dependent enzyme (luciferase), we provide evidence
100 for accumulation of genistein in the organism that may persist
for at least 2 weeks. When, following fasting, it is mobilized
from body stores, it reaches blood levels that are sufficient to
induce estrogenic effects in reproductive and nonreproductive
target organs and to counteract or cooperate with the estrogenic
105 or antiestrogenic action of industrial xenoestrogens. Interaction
between these two types of estrogens may affect the endocrine
system, depending on their relative concentrations, their
affinities for the ERs, and their synergistic or mutually
competing actions. The actions of phytoestrogens may protect
110 organisms from the actions of ER-interacting pollutants and
interfere with the actions of physiological estrogens.
MATERIALS AND METHODS
Experimental Animals
The procedures involving the animals and their care were conducted in
115 accord with institutional guidelines, which comply with national and in-
ternational laws and policies (National Institutes of Health, Guide for the Care
and Use of Laboratory Animals, 1996 [7th edition] [Washington, DC]; National
Academy Press, National Research Council Guide, http://www.nap.edu/read-
ingroom/books/labrats). The ERE-tK-luciferase mouse model (ERE-tK-LUC)
120 has been extensively studied in our laboratories for testing the mode of action of
the chemicals used in these experiments: organochlorines (Di Lorenzo et al.,
2002; Mussi et al., 2005; Penza et al., 2004; Villa et al., 2004), genistein (Brena
et al., 2005; Penza et al., 2006), and estradiol (Ciana et al., 2001, 2003), with
respect to their dose response, time course, specificity, sensitivity, and agonism/
125 antagonism of ER ligands. ERE-tK-LUC transgenic mice were kept in animal
rooms maintained at a temperature of 23C, with natural light/dark cycles. For
the experiments, we used heterozygous littermates obtained by mating our
founders with C57BL/6J wild-type mice. Two-month-old heterozygous trans-
genic male mice of an average weight of 25 g were screened by polymerase
130 chain reaction analysis for the presence of the transgenic cluster. Before all
treatments, the mice were put on an estrogen-free diet (Piccioni, Milan) for
1 week. For the acute treatments, heterozygous male mice (2 months old) were
injected ip with 100 ll of 17b-estradiol or bBHC or orally treated with
genistein at the needed concentration or with 100 ll of vehicle (vegetable oil) as
135control. For loading of compounds, the animals were treated ip for three
consecutive days with 100 mg/kg of bBHC or 50 lg/kg of 17b-estradiol and
orally with 50 mg/kg of genistein. The mice with an average body weight of
25 g (± 2 g) were then put into groups that were either fasted for 48 h or fed
ad libitum. The animals were sacrificed by cervical dislocation and the tissues
140dissected and immediately frozen on dry ice. Tissue extracts were prepared by
homogenization in 500 ll of 100mM K2PO4 lysis buffer (pH 7.8) containing
1mM dithiothreitol, 4mM ethyleneglycol-bis(aminoethylether)-tetraacetic
acid, 4mM ethylenediaminetetraacetic acid, and 0.7mM phenylmethylsulfo-
nylfluoride, with three cycles of freezing/thawing and 30 min of microfuge
145centrifugation at maximum speed. Supernatants, containing luciferase, were
collected, and protein concentration was determined by Bradford’s assay
(Bradford, 1976).
Chemicals
We purchased 17b-estradiol (17b-E2) and genistein from Sigma (Pomezia,
150Italy). bBHC, p,p#-DDT [1,1,1,-trichloro-2,2-bis(p-chlorophenyl)ethane], and
o,p#-DDT [1,1,1,-trichloro-2(p-chlorophenyl)-2-(o-chlorophenyl)ethane] were
purchased from Superchrom (Milan, Italy).
Enzymatic Assay
Luciferase enzymatic activity was measured, as reported by de Vet et al. (de
155Vet et al., 1987; Gould and Subramani, 1988), in tissue extracts at a protein
concentration of 1 mg/ml. The light intensity was measured with a luminometer
(Digene Diagnostics) over 10 s and expressed as relative light units/mg proteins.
Genistein Assay
Chow samples preparation. Four grams of each chow sample was ground
160with a mill and extracted with 100 ml of 70% ethanol, adjusted to pH 3.2 with
formic acid for one night at room temperature. The extracts were defatted with
33 50 ml of petroleum ether. The defatted extracts were evaporated to dryness
under vacuum at room temperature, and finally redissolved in EtOH/H2O
(70:30 pH 3.2 with formic acid), to a final volume of 7 ml.
165Plasma samples preparation. Sample preparation for plasma isoflavones
analysis was performed according to the methods described by Manach et al.
(1998), appropriately modified. To limit the isoflavones losses, a simple
treatment procedure was used: 900 ll plasma was acidified with 100 ll of
0.58M acetic acid solution. The acidified plasma samples were mixed with the
170enzymes, 5 ll b-glucuronidase and 80 ll arilsulfatase, and treated for 30 min at
37C. For the isoflavones extraction, the samples were mixed with 2.75 ml of
acetone, shaken for 1 h, and subsequently centrifuged at 24003 g for 45 min at
4C. The supernatant of each sample was dried by speed vacuum at room
temperature. The organic phase was than redissolved in 300 ll of methanol and
175200 ll of water. Before being injected in the high-performance liquid
chromatography (HPLC) system, the samples were centrifuged by microfuge
for 2 min, and 50 ll of clear samples were tested by HPLC.
HPLC-DAD analysis. The analyses were carried out using an HP 1100L
liquid chromatograph equipped with a DAD detector (Agilent Technologies,
180CA), and a dual pump 515 model liquid chromatographic system, supplied with
a diode array system Model 996 (Waters Corporation, MA). Isoflavonoids were
separated using a 150 3 3.9 mm (4 lm) Nova Pak C18 column (Waters
Corporation) operating at 30C. The mobile phase was a four-step linear
solvent gradient system, starting from 95% H2O (adjusted to pH 3.2 by H3PO4)
185up to 100% CH3CN during a 27-min period (Romani et al., 2003), the flow rate
was 0.8 ml/min.
High-performance liquid chromatography–mass spectrometry anal-
ysis. High-performance liquid chromatography–mass spectrometry (HPLC-
MS) analyses were performed using an HP 1100 MSD API, ESI interface,
190coupled with an HP 1100L liquid chromatography equipped with a DAD
detector (Agilent Technologies). The HPLC-MS analysis was performed using
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the same HPLC-DAD condition with water adjusted to pH 3.2 by HCOOH.
Mass spectrometer operating conditions were: nitrogen gas temperature 350C
at a flow rate of 12 l/min, nebulizer pressure 30 psi, quadrupole temperature
195 30C, and capillary voltage 3500 V. The mass spectrometer operated in positive
and negative mode at 80–180 eV fragmentor values.
Identification of genistein was carried out using its retention time and both
spectroscopic and spectrometric data. Genistein was quantified by a five-point
regression curve (r2 ¼ 0.9994) operating in the range 0–12 ng on the basis of
200 authentic standard, and determination was directly performed by HPLC-DAD.
Gas Chromatography–Mass Spectrometry Analysis of bBHC
Sample extraction. One milliliter of serum was added to 2 ml of methanol
and shaken for 30 min. The mix was than added with 6 ml of n-hexane/diethyl
ether, shaken for 30 min, and centrifuged for 10 min at 2000 rpm. Four
205 milliliters of the solution was concentrated to 1 ml in a vacuum evaporator and
eluted on a Florisil cartridge (6 ml, 1 g; Supelco, Bellefonte, PA) and a silica
cartridge (6 ml, 1 g; Supelco) sequentially. The extracts were brought to
dryness, and the derivatives were dissolved in n-hexane (100 ll). As internal
standard, a solution of 2,4,6-trichlorobiphenyl (1 lg/ml) was used.
210 Gas chromatography–mass spectrometry analysis. Two microliters of the
extracts was injected in gas chromatography–mass pectrometry (GC-MS) and
separated by chromatography on a PONA fused silica capillary column (HP,
CA) with helium as carrier gas (flow rate, 1 ml/min constant flow) and by
temperature programing (injector 240C, detector 320C). The instrument used
215 was a GC HP 6890 MS HP 5972-A (HP). p,p#-DDT, p,p#-DDE, and bBHC
were identified by single-ion monitoring methods by the following ions: 217/
219, 235/237, 246/248. They were quantified by the standard addition method
(10 and 100 ng/ml solutions). Concentrations are expressed as micrograms per
milliliter.
220 Statistical Analysis
Statistical analysis was performed by two-way ANOVA test followed by
post hoc Bonferroni analysis.
RESULTS
Genistein Released from Body Depots Reaches Estrogenic
225 Levels in the Organism
We have assessed ERE-dependent luciferase expression in
estrogen-reporter mice (Ciana et al., 2001) before and after 48 h
of fasting in genistein-, bBHC-, 17b-estradiol–, and vehicle-
loaded mice.
230 Thirty ERE-tK-LUC mice per group were loaded with 50
mg/kg/day of genistein, or 100 mg/kg/day of bBHC, or 50 lg/
kg/day of 17b-estradiol, or vehicle for three consecutive days
(accumulation phase). Compound-loaded and control mice
were left untreated for 15, 30, or 90 days on an estrogen-free
235 diet and assessed for the presence of residual estrogenic
activity in a reproductive and a nonreproductive tissue (testis
and liver; Fig. 1, white bars). Luciferase activity significantly
above control levels was detectable at 15 days in the livers of
mice loaded with bBHC (p < 0.05), indicating the persistence of
240 this compound in the body. No activity on reporter expression
was detected in genistein- and estradiol-loaded mice.
We then verified if fasting could induce an increase in
compound bioavailability sufficient to affect ERE-dependent
gene expression. Fifteen mice from each group were fasted for
24548 h. Fasting itself caused a dramatic reduction in reporter
activity in the liver, to 20% of the control value (p < 0.001), and
significantly activated the ERs in the testis (1.7-fold induction;
p < 0.001).
In the genistein- and bBHC-treated groups, compound mobi-
250lization at 15 days reached sufficient levels to strongly reverse
fasting-induced reporter downregulation in the liver (twofold and
threefold induction, respectively; Fig. 1A). After 30 days, the
fasting mobilized bBHC to levels sufficient to upregulate the
reporter (1.9-fold induction), while at 90 days luciferase
255expression was not higher than in fed mice, although it was not
significantly lower as in the unloaded group. In the genistein-
loaded group, after 30 days, reporter expression was not repressed
by fasting as it was in control mice, indicating some residual
activity of the phytoestrogen that was not visible at 90 days.
260In the testis, although fasting itself slightly activated the
ERs, at 15 days bBHC inhibited, while genistein significantly
induced luciferase expression (Fig. 1B). The effect of bBHC at
30 days was less evident. At this time, the action of genistein
was not significantly different from the control.
265No differences in ER activity were detected in 17b-E2–
loaded mice before or after 48 h of fasting, compared to
vehicle-treated mice, indicating clearance of the estrogen
shortly after loading. We have shown in recent works that
17b-E2 activity peaks at 6 h in tissues of these mice as
270measured by luciferase activity, than is rapidly catabolized. At
24 h, luciferase is back to basal level (Ciana et al., 2001, Villa
et al., 2004). Possible alterations of the luciferase enzyme
activity were tested in vitro after adding 17b-estradiol,
genistein, and bBHC to the enzyme reaction. No changes were
275observed, indicating that the function of the enzyme is not
directly affected by the chemicals (not shown).
Serum Levels of Genistein Mobilized during Starvation
To verify if the observed differences in reporter activation in
the genistein- and bBHC-loaded and fasted mice were due to
280the mobilization of the compound, we made a quantitative
evaluation of the circulating levels of genistein and bBHC.
HPLC-DAD and HPLC-MS analysis were performed on the
sera of untreated and genistein-loaded mice before and after the
48-h fasting period. GC-MS was used to assay bBHC.
285As shown in Figure 2, fasting was accompanied by an in-
crease in genistein levels from 99 ± 13 to 163 ± 17nM (p< 0.05).
bBHC increased from 74 ± 16 to 176 ± 33nM (p < 0.05).
Genistein Inhibits the Activity of bBHC on the
ERE-Dependent Reporter in the Testis of Loaded,
290Fasted Mice
We have shown that bBHC inhibits ERE-dependent lucifer-
ase expression in the testes of 2-month-old male mice loaded
with the chemical and fasted (48 h) after 15 days, thus acting as
an antiestrogen. We set up an experiment in which mice were
295loaded with bBHC (300 mg/kg/3 days), genistein (150 mg/kg/3
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days), or both compounds in combination. After 15 days of
resting, mice were fasted for 48 h, and luciferase activity in the
testis was recorded. bBHC and genistein were mobilized and
targeted the testis with opposite actions on the ERE-dependent
300 reporter (Fig. 3). In mice loaded with both compounds
simultaneously, genistein was able to revert the antiestrogenic
action of bBHC.
Genistein Antagonizes or Cooperates with the Action of
Organochlorines and Estradiol in Testis and Liver of
305Acutely Treated Estrogen-Reporter Mice
We have previously reported that the DDT isomer o,p#-DDT
is an efficient antiestrogen in the liver, while p,p#-DDT acts as
an agonist through ER-mediated mechanisms (Di Lorenzo
et al., 2002). The following experiment demonstrates that, in
310the liver, genistein is able to counteract the antiestrogenic
action of o,p#-DDT, cooperates with that of the ER agonist
p,p#-DDT, and antagonizes the positive action of estradiol.
o,p#-DDT (50 mg/kg) inhibited the expression of luciferase
down to a level 35% of the control value. Coadministration of
315genistein in a dose-response experiment reversed the antiestro-
genic effect of o,p#-DDT and induced the reporter twofold at
the nutritional dose of 5000 lg/kg (Fig. 4A). Genistein’s action
was additive with that of p,p#-DDT (Fig. 4B). At the same
doses, genistein also inhibited the estrogenic effect of physi-
320ological concentrations of 17b-E2 (5 lg/kg) (Fig. 4C).
bBHC (50 mg/kg) inhibited luciferase expression in the
testis by 65%. Genistein at 5000 lg/kg reversed this effect
FIG. 2. Measurements of genistein and bBHC in serum. The serum of
genistein- and bBHC-loaded mice was analyzed for changes in levels of
genistein or bBHC, before and after fasting. The white bars indicate the
concentration of genistein or bBHC in serum of compound-loaded mice before
fasting (day 15 from loading) and the gray bars the concentrations after 48 h of
fasting (day 17 from loading). Values are expressed as nanomoles of genistein
or bBHC per liter of serum. The determinations were repeated twice on five
mice per group. GEN, genistein-loaded mice ± 48 h fasting; bBHC, bBHC-
loaded mice ± 48 h fasting. Bars represent the average ± SE; *p < 0.05, as
compared with the controls.
FIG. 1. Effect of fasting on reporter regulation in transgenic mice loaded with bBHC, genistein, or 17b-estradiol. Mice were put on an estrogen-free diet for
1 week before any treatment and for the entire course of the experiments. Mice were loaded with 50 mg/kg, 100 mg/kg, or 50 lg/kg of genistein (oral gavage),
bBHC (ip), or 17b-estradiol (ip), respectively, or vehicle (30 mice per group) once a day for three consecutive days and left without any other treatment for the
following 15, 30, or 90 days. Luciferase activity in the liver (A) and testes (B) of genistein-, bBHC-, 17b-estradiol– or vehicle-loaded mice after 15, 30, or 90 days
on an estrogen-free diet, with or without 48 h of fasting. Fifteen mice from each group were then put on complete food deprivation for 48 h, with water ad libitum.
At the end of the fasting period, all the mice were sacrificed and the tissues collected and stored at 80C until assayed. Luciferase activity is expressed as relative
light units normalized to protein concentration. The half-life of the luciferase enzyme used to generate these mice is 3 h (not shown). The experiments were
repeated twice. Bars represent the average ± SE; *p < 0.05; **p < 0.001, as compared with the controls.
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(Fig. 4D). In this organ, genistein did not significantly change
the extent of luciferase induction by p,p#-DDT or estradiol
325 (Figs. 4E and 4F). Possible alterations of the luciferase enzyme
activity were tested in vitro after adding 17b-estradiol,
genistein, o,p#-DDT, and p,p#-DDT to the enzyme reaction.
No changes were observed, indicating that the function of the
enzyme is not directly affected by the chemicals (not shown).
330 These results indicate that nutritional doses of genistein
inhibit the hormonal effects of xenoestrogens in tissues of male
mice and may interfere with the physiological action of estradiol
DISCUSSION
Genistein is a nutritional isoflavone that possesses hormonal
335 activity through its binding to various nuclear receptors (Dang
et al., 2003; Gao et al., 2004; Kuiper et al., 1998). The best
characterized is its action through the ERs, ERa and ERb, by
which it induces several biological responses that may be
beneficial for human health. For this reason, genistein has been
340 proposed as a potential therapeutic compound that should be
integrated into our diets (Beck et al., 2005). Its effects, as
observed in mouse models, are dependent on dose and gender
(Penza et al., 2006; Slikker et al., 2001), so the ‘‘healthy’’ safe
dose should be defined and the biology of this molecule better
345 characterized before it is put to pharmacological use. Pharma-
cokinetics and pharmacodynamics studies on genistein have
been conducted in animal models (Chang et al., 2000) and
humans (King and Bursill, 1998; Watanabe et al., 1998), in
which it appears that it is quickly eliminated from plasma,
350 dropping to residual levels 12–24 h from administration (King
and Bursill, 1998) with gender-specific pharmacokinetics
(Chang et al., 2000; Watanabe et al., 1998). Our results
establish that part of the consumed genistein may transiently
accumulate in the body, persisting for weeks at preferential
355sites of accumulation from which it is mobilized during energy
imbalance. In rats, the largest amount of the absorbed
compound is not found in fat (Coldham and Sauer, 2000).
Maximum concentrations were measured in the small intestine
and cecum at 2 and 7 h after administration. The liver, plasma,
360and reproductive tissues, including uterus, ovary, vagina, testis,
prostate, and prostatic fluid, also accumulate higher concen-
trations of genistein than other peripheral organs (Chang et al.,
2000; Hedlund et al., 2005, 2006; Rannikko et al., 2006).
Fasting induces genistein mobilization in loaded mice, in
365which it reaches a serum level of 163nM after 48 h of fasting.
This concentration is below the Ki for tyrosine kinase in-
hibition, supporting a receptor-mediated action in target cells.
There are also nonnutritional, synthetic estrogenic com-
pounds that contaminate food and are consumed daily with the
370diet. Several organochlorines, for example, have been charac-
terized as estrogenic (Di Lorenzo et al., 2002; Kuiper et al.,
1998); they are environmentally ubiquitous and can enter the
food chain and accumulate in the adipose tissues of animals
and humans, where they can remain for years (Safe, 1992),
375accumulating to higher levels with advancing age (Lordo et al.,
1996). Periodically, mainly in physiological situations associ-
ated with dietary restrictions (Beaufrand et al., 1978; Bigsby
et al., 1997; Herron and Fagan, 2002), they are mobilized,
increase their blood levels, and may evoke an abnormal
380estrogenic or antiestrogenic response.
Concern over the activity of environmental estrogens is in
regard to their action as ER modulators in the whole body and
its suspected link to chronic and degenerative diseases (Den
Hond and Schoeters, 2006; Hoyer, 2001).
385In this work, we have characterized the total estrogenic action
deriving from simultaneous exposure to estrogens from different
classes, including physiological, nutritional, and environmental
estrogens. We found that the estrogenic action of a toxic
environmental compound may be influenced by the presence of
390nutritional estrogens such as genistein. These natural compounds
are generally consumed with the diet at higher concentrations
than contaminating chemicals. Phytoestrogens are consumed
in milligram amounts per day (Aldercreutz et al., 1993; Bhakta
et al., 2006 Kimira et al., 1998), while environmental chemicals
395such as organochlorines and other persistent pesticide residues
are consumed in nanogram amounts per day (Simonich
and Hites, 1995). Dietary hormones are also present in blood at
much higher concentrations, and their affinity toward ERs,
especially for ERb, is higher than those of several xenoestrogens
400(Kuiper et al., 1998). Competition between the different ligands
for binding to ERs may result in overlapping or contrasting
actions on the regulation of target genes. The outcome of this
competition may be dependent on each compound’s relative
affinity for the receptors (Kuiper et al., 1998).
FIG. 3. Effect of fasting on reporter regulation in testes of transgenic mice
loaded with bBHC or genistein or both. Luciferase values in the testes of
genistein-, bBHC-, genistein-plus-bBHC– and vehicle-loaded mice, after 15
days of resting on an estrogen-free diet and after 48 h of fasting. Mice were put
on an estrogen-free diet for 1 week before any treatment and for the entire
course of the experiments. Mice were loaded with 100 mg/kg of bBHC (ip), 50
mg/kg of genistein (oral gavage), or both compounds in combination once
a day, for three consecutive days (total bBHC and genistein 300 and 150 mg/kg,
respectively) and left without any other treatment for the following 15 days (20
mice per group). Ten mice from each group were then put on complete food
deprivation, with water ad libitum. At the end of the 48 h of fasting, all the mice
were sacrificed and the tissues collected and stored at  80C until assayed.
Luciferase activity is expressed as relative light units normalized to protein
concentration. The experiments were repeated twice. V, vehicle; GEN,
genistein. Bars represent the average ± SE; *p < 0.05; **p < 0.001, as
compared with the controls.
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405 While genistein acted in the liver by antagonizing the
antiestrogenicity of the organochlorines, it itself displayed
antiestrogenic characteristics in the presence of estradiol. The
molecular interaction among different agents at the receptor
level has particular importance because nutritional phytoes-
410 trogens can modify responses to physiological estrogens and
toxic compounds. Competition with toxic compounds should
have favorable effects on human health and might represent
a new rationale for dietary advice. Interference with estradiol
has unknown outcomes and should be studied in more detail
415 during development, at different ages, during pathological
states, and in a gender-specific manner.
Genistein, when given as a single oral bolus and when
mobilized from body stores weeks after administration,
competed with the action of o,p#-DDT and bBHC in liver
420 and testis, respectively, and interfered with estradiol action in
the liver. Less striking was the interaction of genistein with the
ER agonist p,p#-DDT in mice cotreated with both ER ligands,
in which case we observed an additive effect on the reporter in
the liver, which was not visible in the testis.
425A tissue-specific pharmacodynamic of genistein and estra-
diol may be responsible for the different combined interactions
observed in the organs analyzed.
These data show that genistein is an efficient estrogen in the
tissues analyzed. However, at the nutritional dose of 5000 lg/
430kg body weight, while being an agonist in both the liver and
testis when given alone, it appears to behave as a partial
antagonist when given in conjunction with physiological doses
of estradiol. This is probably due to the 100-fold lower potency
of genistein on ERs compared to estradiol and, as recently
435observed in our laboratory, to the fact that genistein strongly
downregulates ERa in the liver, thus antagonizing ERa
upregulation by estradiol (not shown).
The simultaneous presence of different ER ligands affects
the response of the compounds given singly. Genistein at
440dietary doses counteracted the inhibitory action of bBHC on
FIG. 4. Genistein interferes with the action of organochlorines and estradiol. (A and B) Adult mice were injected with oil or an oil solution of 50 mg/kg o,p#-
DDT (A) or p,p#-DDT (B) and kept for 16 h. At 6 h after injection, the mice were orally treated with increasing concentrations of genistein (50, 500, or 5000 lg/kg)
and kept for the remaining 10 h. The single dose of the administered organochlorines was chosen from previous experiments already published (Di Lorenzo et al.,
2002; Mussi et al., 2005; Penza et al., 2004; Villa et al., 2004). Controls were orally treated with vegetable oil. (C) Adult mice were injected with oil or an oil
solution of 5 lg/kg 17b-E2, kept for 6 h, and orally treated for the same time with increasing concentrations of genistein (50, 500, or 5000 lg/kg). Luciferase
activity was measured in livers and testis (F) of mice killed at defined time points after treatment. The experiments were repeated three times with a total of six
animals per group. (D and E) Adult mice were injected with oil or an oil solution of 50 mg/kg bBHC (D) or 50 mg/kg p,p#-DDT (E) and kept for 16 h. At 6 h after
injection, the mice were orally treated with increasing concentrations of genistein (50, 500, or 5000 lg/kg) and kept for the remaining 10 h. Controls were orally
treated with vegetable oil. Doses of genistein are plotted on a logarithmic scale. (F) Mice were treated as in (C). The half-life of the luciferase enzyme used to
generate these mice is 3 h (not shown). The experiments were repeated three times with a total of six animals per group. Bars represent the average ± SE of two
individual experiments, each performed in triplicate. *p < 0.05, **p < 0.001, as compared with the control.
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the ERE reporter in the mouse testis when the compounds were
mobilized from body stores. Accumulation followed by fasting
was used to minimize the differences in the toxicokinetics of
the two compounds (they are much faster for genistein than for
445 bBHC) when they were given acutely (Penza et al., 2004; Villa
et al., 2004). The fact that the levels of genistein released
during fasting are capable of altering the toxicological behavior
of bBHC and o,p#-DDT allows us to hypothesize that it is also
effective in changing the effect of other toxicants active
450 through the ERs. Interactions of genistein with other endocrine-
disrupting agents have recently been reported (Wang et al., 2006;
You et al., 2004), although it was not clear that the interaction
between the compounds analyzed, genistein and methoxychlor,
was occurring through the ERs. Data on the interaction between
455 two or more chemicals are important in interpreting toxicological
experiments in animals exposed to single chemicals and for the
epidemiological evaluation of the effects of pollutants on human
health in countries with different traditional diets.
In this work, we have analyzed the acute and delayed action
460 of genistein following accumulation/fasting release, through
the ERs; however, other mechanisms could be involved. For
instance, while the results here strongly indicate a dose-
dependent effect following liberation of genistein from body
stores, it must be kept in consideration that the analytical
465 methods used measured total serum genistein after cleaving
glucuronide and sulfate conjugates. Since conjugated forms of
genistein are not active toward the ER, this analysis may
overestimate the actual activity of genistein in the serum, since
over 95% of circulating genistein is usually conjugated.
470 Therefore, while the experiments strongly indicate that this
‘‘unloading’’ is the cause of the changes observed in luciferase
reporter activity, one cannot rule out a pharmacodynamic
effect. There are different possible mechanisms that may
participate to modulate the end point used in our model
475 (luciferase). For instance, the 3-day ‘‘loading’’ of genistein
may cause changes in steroidogenesis or steroid metabolism
that can persist for 2 weeks, perhaps magnified by the effects of
fasting which is known to alter enzyme activities. We are
currently studying the serum concentrations of free (unconju-
480 gated) genistein to understand which of these two possible
mechanisms is responsible for the observed effects.
Another effect of the chemicals used in our study that might
add a further level of complexity to the performed analysis is the
regulation of peripheral estrogen synthesis. However, although
485 organochlorines and genistein may regulate aromatase, this was
not an effect that changed our data. In fact, the state of ER
activation in these animals was monitored with or without
coadministration of the aromatase inhibitor Arimidex (0.5 mg/
kg). Although this treatment was able to block the female estrous
490 cycle in a parallel experiment, we did not observe changes
in luciferase activity that reached significance (not shown).
Environmental estrogens have been found to vary in their
capacity to mobilize from sites of accumulation and, conse-
quently, to have different biological actions on the uterus
495(Bigsby et al., 1997). We found that the isoflavone genistein
can also accumulate in the body and be mobilized during
periods of energy imbalance. Although it is much less
persistent than the organochlorines we tested and other in-
dustrial chemicals, its serum concentration increased during
500fasting and reached estrogenic levels in mice previously loaded
with this compound. These results seem to indicate that some
dietary regimens may favor genistein accumulation and its
bioavailability, which in turn may result in fluctuating estro-
genic actions that may antagonize or provide an additive effect
505to other environmental or endogenous estrogens.
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